KEGG   DRUG: CanakinumabHelp
Entry
D09315                      Drug                                   

Name
Canakinumab (USAN/INN);
Canakinumab (genetical recombination) (JAN);
Ilaris (TN)
Product
Formula
C6452H9958N1722O2010S42
Exact mass
145065.8205
Mol weight
145155.1643
Remark
Therapeutic category: 
ATC code: 
Activity
Anti-inflammatory diseases, IL-1 beta antagonist
  Disease
Cryopyrin-associated periodic syndromes [DS:H00282]
Comment
Monoclonal antibody
Target
IL1B [HSA:3553] [KO:K04519]
  Pathway
MAPK signaling pathway
Cytokine-cytokine receptor interaction
NOD-like receptor signaling pathway
Interaction
Drug interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L04 IMMUNOSUPPRESSANTS
   L04A IMMUNOSUPPRESSANTS
    L04AC Interleukin inhibitors
     L04AC08 Canakinumab
      D09315  Canakinumab (USAN/INN)
USP drug classification [BR:br08302]
 Immunological Agents
  Immunomodulators
   Canakinumab
    D09315  Canakinumab (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 3  Agents affecting metabolism
  39  Other agents affecting metabolism
   399  Miscellaneous
    3999  Others
     D09315  Canakinumab (USAN/INN); Canakinumab (genetical recombination) (JAN)
Target-based classification of drugs [BR:br08310]
 Cytokines
  IL-1 family
   IL-1B
    Canakinumab
     D09315  Canakinumab (USAN/INN)
New drug approvals in the USA [br08319.html]
 New Molecular Entity and New Therapeutic Biological Product Approvals
  D09315
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D09315
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D09315
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D09315
Orphan drugs in the USA [br08355.html]
 Orphan drugs in the USA
  D09315
BRITE hierarchy
Other DBs
CAS: 
914613-48-2
PubChem: 

» Japanese version   » Back

DBGET integrated database retrieval system